OmniAb Inc. logo

OmniAb Inc.

OABI | NASDAQ
Chart Builder DCF Calculator
$4.58
+$0.11 (+2.46%)
At close: Sep 21, 2026, 4:00 PM ET
$4.60
+$0.02 (+0.44%)
Pre-market: Sep 22, 2026, 4:00 AM ET

Company Profile

OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.

Key Executives

Name Position
Matthew W. Foehr President, Chief Executive Officer & Director
Amechi Nwachuku Executive VP & Chief Operating Officer
Charles S. Berkman Chief Legal Officer
Kurt A. Gustafson Executive Vice President of Finance & Chief Financial Officer
Bill Harriman Senior Vice President of Discovery Partnership Mgt., Technology Development & Operations
Bob Chen Senior Vice President of Discovery Systems
Christel Iffland Senior Vice President of R&D Portfolio Management and Technology Operations
Cia McCaffrey Senior Vice President of People & Talent
Todd Pettingill Vice President of Business Development & Strategy
Yasmina Noubia Abdiche Senior Vice President of Exploratory Research

Latest SEC Filings

Date Type Title
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 06, 2026 10-Q Quarterly Report
Aug 06, 2026 8-K Current Report
Aug 03, 2026 4 Filing
Jul 13, 2026 3 Filing
Jul 13, 2026 8-K Current Report
Jun 18, 2026 4 Filing
Jun 18, 2026 4 Filing
Jun 18, 2026 4 Filing
Jun 18, 2026 4 Filing
View All SEC Filings
OmniAb Inc.
OmniAb Inc. logo
Country United States
IPO Date Sep 29, 2021
Industry Biotechnology
Sector Healthcare
Employees 89
CEO Matthew W. Foehr

Contact Details

5980 Horton Street EmeryVille, California 94608 United States

Stock Details

Ticker Symbol OABI
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001846253
CUSIP Number 68218J103
ISIN Number US68218J1034
SIC Code 8731

© 2026 bestshares.com. All rights reserved.